Meet with...NCI and NHLBI

Add this event to your calendar:
07/09/2017 12:00 07/09/2017 13:45 America/Los_Angeles Meet with...NCI and NHLBI Johnson & Johnson Innovation, JLABS , 329 Oyster Point Blvd , South San Francisco , CA JLABS Bay Area false DD/MM/YYYY
September
7
Event

Meet with...NCI and NHLBI

Johnson & Johnson Innovation, JLABS , 329 Oyster Point Blvd , South San Francisco , CA

September 07, 2017 from 12:00 PM to 13:45 PM (PDT)

$10 - $35


The National Cancer Institute Small Business Innovation Research (NCI SBIR) is returning to the Bay Area. This year they will be joined by representatives from the National Heart, Lung, and Blood Institute(NHLBI), Division of Cardiovascular Sciences. The joint presentation will be held on September 7th with 1-on-1* meetings, for accepted companies, scheduled on September 7th and 8th.

*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due by August 18th. Apply Here.

On Thursday, September 7th, Greg Evans, NCI SBIR and Kurt Marek, NHLBI will highlight funding opportunities and other resources for startups in the cancer and cardiovascular sciences.

Program Overview:
NCI and NHLBI Present Current and New Funding Opportunities
The representatives will discuss the exciting new non-dilutive targeted funding opportunities in cancer and cardiovascular focused technology development. They will explain the application and review process at the NIH to help small businesses submit stronger applications. The team will discuss key requirements, timelines, important contacts as well as the best practices for successful applications. Additionally, the presentation will touch on the I-Corps at NIH program and other initiatives to facilitate the success of SBIR companies. .

Following the presentation on Thursday afternoon, September 7th and Friday September 8th, the NCI and NHLBI will meet with selected companies for 1-on-1 meetings. To be considered for a one-on-one meeting, please apply here, by August 17th.

Co-hosted with:


Speakers:
Kurt Marek, Ph.D. | Deputy Director, National Heart, Lung, and Blood Institute read bio»
Greg Evans Ph.D.
| Supervisory HSA and Team Leader, Cancer Imaging/ Biology/ Control , SBIR Development Center, National Cancer Institute read bio»


Agenda:
Thursday September 7th
10:00AM | Registration and Networking
10:30 AM | Presentation and Q&A
11:45 AM | Networking Lunch
1:00-5:15 PM | One-on-One Meeting*

Friday September 8th
10:00AM to 4:00PM | 1-on-1 meetings
*30 minutes each

*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due August 17th. Apply Here.


Fees:

Presentation
$25 | General Public
$35 | Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on September 6th (or sold out).

One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Apply to meet one-on-one with representatives from NCI and NHLBI Your application will be reviewed and you will be notified of acceptance on Thursday, August 24th 2017. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.


Speakers' Biographies:

Kurt Marek, Ph.D. | Deputy Director, National Institutes of Health/NHLBI Office of Translational Alliances and Coordination

Office of Translational Alliances and Coordination Dr. Marek is the Deputy Director of the Office of Translational Alliances and Coordination (OTAC) at the National Heart, Lung, and Blood Institute (NHLBI). OTAC is charged with developing trans-NHLBI programs to foster the translation of early stage discoveries into commercial products. The Office coordinates the NIH Centers of Accelerated Innovations and the Institute's small business program. Dr. Marek is the Program Director for the NIH Research and Commercialization Hubs program and oversees the Institute's efforts to support small businesses performing research and development on innovative biomedical products and to facilitate partnerships between small businesses, investors and strategic partners. Dr. Marek has received numerous awards over the course of his government service, and has served as an organizer of and speaker at national conferences.


Greg Evans Ph.D. | Supervisory HSA and Team Leader, Cancer Imaging/ Biology/ Control , SBIR Development Center, National Cancer Institute

Dr. Greg Evans is a molecular biologist/biochemist by training who has worked at NIH for 26 years. He has 19 years experience as an NIH Program Director managing early-stage, bench-to-bedside (Translation I) research projects. Since June of 2008, Dr. Evans has served as a Team Leader and Program Director within the National Cancer Institute (NCI) SBIR Development Center, an office created in 2007 to centralize management of all NCI SBIR/STTR funding, to increase marketing efforts in the small business and biotechnology investment communities, and to raise the bar for commercialization of cancer-related products and services by small businesses. As a Team Leader and Supervisor, Dr. Evans leads a group of 5 Program Directors responsible for small business projects in the imaging, cancer biology, and behavioral medicine areas. As a Program Director, he is responsible for a technically diverse portfolio that includes projects focused on imaging devices, drug development, diagnostics, basic cancer biology, and population-based cancer prevention.

Prior to coming to the NCI SDC, Dr. Evans worked from 1998-2008 as a Program Director for research on hemoglobin disorders within the Blood Division of the National Heart, Lung, and Blood Institute (NHLBI) at NIH. In that capacity, he managed for five years the Comprehensive Sickle Cell Centers Clinical Trials Consortium, a 20-institution academic collaborative group funded to develop and implement collaborative Phase I-II clinical studies in sickle cell disease. Dr. Evans played a lead role coordinating and facilitating the development of 7 collaborative clinical studies. He also managed a joint NHLBI-Pfizer project for a Phase II/III contract clinical trial of Sildenafil (Viagra) for pulmonary hypertension secondary to sickle cell disease. In that effort, he played a key role in the development of an Independent Research Grant Agreement with Pfizer that covered donation of the study medication and matched placebo, as well as Pfizer's special requirements for adverse event reporting. In addition, while with NHLBI Dr. Evans managed three projects under the NIH RAID (Rapid Access to Intervention Development) program, all of which involved both academic and commercial stakeholders. Lastly, he served on NHLBI-wide programs focused on translational research (e.g. Programs of Excellence in Gene Therapy, 2000-2005; Programs for Genomic Applications, 2000-2008).

Prior to moving to NHLBI to take a research administration position, Dr. Evans was a Senior Staff Fellow from 1995-1998 at the National Human Genome Research Institute at NIH, where he studied and published on gene therapy for the blood clotting disorder Hemophilia A. Before that, he served from 1991-1995 as a American Cancer Society postdoctoral fellow, and an intramural research and training fellow at the NCI, where he studied and published on MDR1-mediated multidrug resistance in cancer.

Dr. Evans received a Ph.D. in Biochemistry in 1991 from the UCLA, and a B.A. in Biochemistry from UC Berkeley in 1982. He is a native of Santa Rosa, California.



About the Meet With... Series:

The purpose of the Meet with series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, OrbiMed, Osage University Partners, Spectrum 28, Quark Venture, and AbbVie Ventures.

Venue:
JLABS @ SSF
329 Oyster Point Blvd - 3rd Floor
South San Francisco, California
Map It


JLABS Bay Area

About Johnson & Johnson Innovation, JLABS Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and healthtech sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to ten global locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto, Beerse (Belgium), with New York City, opening in June 2018, and Shanghai in 2019. For more information please visit www.jlabs.jnjinnovation.com or follow @JLABS. About Johnson & Johnson Innovation Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson's global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation - JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information please visit www.jnjinnovation.com or follow @JNJInnovation.

Event contact


Related content